Breast Cancer and HRT

There are reports in the media about the risk of Breast Cancer from HRT. It is also said that long-term use of HRT is not recommended. This study was reported in the International Journal of Cancer, and was partly funded by the Cancer Council of NSW. All these reports have to be examined thoroughly and understood. The conclusion we can come to fully supports what I have been saying (and others like me) for some time – Standard, synthetic HRT may increase the breast cancer risk. The women in this study were on the usual, synthetic HRT containing Progestagens, not the natural Progesterone I use. Many of them were on the oral (pill form), which we know increases the risk of breast cancer. Those of you who have been following this blog understand that hormones should always be given transdermally, either by creams or troches. The other difference is that these women were on the “one size fits all” HRT. It is essential that the dose is tailored to the individual person. Finally, if used correctly, using Bioidentical hormones, the research shows that there is significant long-term benefits. ( see my web-site under Menopause Recommendations)

Finally, I have been using BHRT for the last 25 years in over 4000 women. Doing a search of my database reveals about 5% (1 in 20) of my patients have developed breast cancer while on the BHRT. The national average is about 10-12 % (1 in 8) of all women will develop breast cancer. These figures will be  reassuring to those of my patients on BHRT.

Here is one of many studies confirming the above.  More available on my web-site under Safety Of BHRT.

Maturitas. 2008 Jul-Aug;60(3-4):185-201. doi: 10.1016/j.maturitas.2008.07.007. Epub 2008 Sep 5.

Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.

Author information

  • 1Department of Gynecology and Obstetrics, Université Libre de Bruxelles, Bruxelles, Belgium. marc.lhermite@chu-brugmann.be

Abstract

Hormone replacement therapy (HRT) in young postmenopausal women is a safe and effective tool to counteract climacteric symptoms and to prevent long-term degenerative diseases, such as osteoporotic fractures, cardiovascular disease, diabetes mellitus and possibly cognitive impairment. The different types of HRT offer to many extent comparable efficacies on symptoms control; however, the expert selection of specific compounds, doses or routes of administration can provide significant clinical advantages. This paper reviews the role of the non-oral route of administration of sex steroids in the clinical management of postmenopausal women. Non-orally administered estrogens, minimizing the hepatic induction of clotting factors and others proteins associated with the first-pass effect, are associated with potential advantages on the cardiovascular system. In particular, the risk of developing deep vein thrombosis or pulmonary thromboembolism is negligible in comparison to that associated with oral estrogens. In addition, recent indications suggest potential advantages for blood pressure control with non-oral estrogens. To the same extent, a growing literature suggests that the progestins used in association with estrogens may not be equivalent. Recent evidence indeed shows that natural progesterone displays a favorable action on the vessels and on the brain, while this might not be true for some synthetic progestins.

Compelling indications also exist that differences might also be present for the risk of developing breast cancer, with recent trials indicating that the association of natural progesterone with estrogens confers less or even no risk of breast cancer as opposed to the use of other synthetic progestins.

In conclusion, while all types of hormone replacement therapies are safe and effective and confer significant benefits in the long-term when initiated in young postmenopausal women, in specific clinical settings the choice of the transdermal route of administration of estrogens and the use of natural progesterone might offer significant benefits and added safety.

PMID:
18775609
[PubMed – indexed for MEDLINE]

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on November 26, 2015, in Uncategorized. Bookmark the permalink. 1 Comment.

  1. Dear Dr Holloway

    I have been subscribed to your blog for a little while and read with interest the regular emails I receive. A friend is also a patient of yours so I follow her health and wellbeing issues as well.

    Many years ago I had the opportunity to join a research program using a troche but at that time I had elevated blood pressure so was discounted and my regular GP at the time didn’t seem to place much importance on it. She did put me on HRT to stabilise my severe menopausal symptoms but I quickly went off it. It did create a change overnight but rather than put up a side effect of the HRT my Dr and I decided I was better off without. Plus I had had a suspect lump in the breast which turned out to be nothing but now I go for 2 yearly mammograms.

    I thought it interesting that this study talks about young post-menopausal women, not post-menopausal women in general.

    Regards,

    Deborah King Contracts Administrator National Service Administration Komatsu Australia Pty Ltd

    535 Progress Road, Wacol, QLD, 4076 PO Box 349, Sumner Park QLD 4074 T: +61732705584[cid:011d-0001@01d1289c.ee9d4ddf] F: +61732705578 M: +61408720954[cid:011d-0001@01d1289c.ee9d4ddf] E: dking@komatsu.com.au W: http://www.komatsu.com.au

    [cid:011d-0002@01d1289c.ee9d4ddf] Please consider the environment before printing this email

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: